Skip to the guide Start Peptide basics The Illinois route Chicago Considering peptides in Illinois Costs Questions My notes A guide to finding care · Chicago, Illinois What would count as a real answer? Someone says there is research behind a treatment. What research, on which product, and for which problem? You can ask those questions without knowing how to read a whole journal paper. The assumption A medicine’s appearance on a government list means it is approved. What the answer rests on FDA stands for Food and Drug Administration, the federal agency that oversees drugs. As of September 2026, it says a National Drug Code does not mean it approved the product. It is an identifying number in a government drug directory. Does that study apply here? Match the claim to the product FDA means the Food and Drug Administration. Approval applies to a specific medicine; a research claim about another version is a different question. Ask whether the study tested the same ingredient, the same tablet or injection, and the same health problem. Was it in people? What did it compare? What did it actually measure? Keep the answers in ordinary words. Compounded means prepared to order. As of September 2026, a generic has its own FDA approval as a version of a brand-name medicine. A made-to-order drug does not have that approval. As of September 2026, FDA calls it misleading to describe a made-to-order drug as a generic. It also calls it misleading to say the drug is proven to give the same result as an approved medicine. The short version Ask for the missing link in the claim What is shown What to ask next A study title Did it study the exact product and problem we are discussing? A result in people What did the study measure, and what were its limits? A government drug code Where is the actual approval record? News of an advisory meeting What final rule or decision followed it? How compounding decisions take shape A meeting is a step in a process A pharmacy preparing an individual patient’s medicine can use FDA’s compounding ingredient list as one route to meeting federal rules. As of September 2026, an ingredient can also qualify through an applicable official drug standard or use in an approved medicine. If neither applies, it needs to be on the compounding ingredient list. The finished medicine still has no FDA approval merely because its ingredient appears on that list. An advisory committee gives FDA advice. As of September 2026, its vote alone does not change the law. Changing the compounding ingredient list requires FDA to put forward a rule, invite public comments, and then reach a final decision. At the July 2026 meeting, the committee discussed semax, epitalon, emideltide, MOTS-c, TB-500, KPV, and BPC-157. If one of those names is on your offer, the meeting alone did not make it lawful to compound. As of September 2026, FDA had published no written summary, verbatim account, or official vote record for the committee’s July 2026 peptide meeting. FDA staff had recommended keeping the peptides discussed there off the compounding ingredient list. People and organisations that asked FDA to consider ingredients for compounding later withdrew some of those requests. As of September 2026, FDA still lists concerns beside those ingredients, including BPC-157, CJC-1295, and injectable GHK-Cu. Withdrawing a request does not mean FDA has cleared the ingredient or approved it. FDA’s concerns include unwanted material and clumping in some peptide products that may make the body’s defences react to them. Studies in people may be missing or too limited to show whether they cause harm. If an offer relies on that meeting or a withdrawn request, ask what rule actually allows the exact product to be made. Ask the person writing the prescription what is known, what remains uncertain, and what that means for your care. Bring the claim back to evidence Which source supports this exact product for my goal, and what does it leave unknown? Keep a question in your notes Evidence for this chapter Chapter notes FDA: what a drug code proves A directory entry is not product approval. FDA: claims about compounded drugs The agency’s guidance on misleading sameness claims. FDA: peptide meeting materials The public record for the advisory meeting. FDA: staff briefing for the meeting The proposals and the role of committee advice. FDA: concerns about nominated ingredients Includes the separate table of withdrawn requests. What can go wrong → Questions for a visit → Explore the care map Start here Start Peptide basics Find care The Illinois route A remote visit Check the person treating you Check a pharmacy Understand the product Made-to-order drugs Check the evidence Pause and check What can go wrong Reasons to pause Plan the cost Understand the bill Ask about coverage Take it to a visit Questions for a visit Keep your questions These pages are a guide to Chicago peptide care; no clinic runs here and no medicine is sold here. Start the care map Chapter notes Read this as text Keep your questions